Your browser doesn't support javascript.

Biblioteca Virtual en Salud

Hipertensión

Home > Búsqueda > ()
XML
Imprimir Exportar

Formato de exportación:

Exportar

Email
Adicionar mas contactos
| |

Long-term outcomes following drug-eluting stent implantation in unprotected left main bifurcation lesions / 中华医学杂志(英文版)

Lei GE; John COSGRAVE; Ioannis IAKOVOU; Ju-ying QIAN; Pierfrancesco AGOSTONI; Giuseppe-M SANGIORGI; Flavio AIROLDI; Iassen MICHEV; Alaide CHIEFFO; Nicola CORVAJA; Antonio COLOMBO; Jun-bo GE.
Chinese Medical Journal ; (24): 545-551, 2007.
Artículo en Inglés | WPRIM | ID: wpr-344858
<p><b>BACKGROUND</b>The safety and efficacy of drug-eluting stents (DES) implantation in unprotected left main (LM) bifurcation lesions has yet to be determined. The aim of the present report was to evaluate the long-term outcome following implantation of DES in unprotected LM bifurcation lesions.</p><p><b>METHODS</b>We identified 70 consecutive patients treated with DES in unprotected LM bifurcation lesions from April 2003 to January 2005. Of them, 42 patients were treated with sirolimus-eluting stent (SES) and 28 patients were treated with paclitaxel-eluting stent (PES).</p><p><b>RESULTS</b>Stents to the left anterior descending and to the circumflex were implanted in 62 patients. During 1-year follow-up, 3 (4.3%) patients died of cardiac causes. One of them had myocardial infarction and adjudicated as possibly due to stent thrombosis. Angiographic follow-up was available in 80% of patients. The per lesion restenosis rate was 13.4% in the entire cohort, of which 10.7% occurred in lesions treated with SES and 16.1% in those treated with PES (P = 0.58). All restenosis was focal and occurred in the lesions treated with a stent with stent size to post-procedural reference vessel diameter ratio < 1.0 (17.6% vs 0, P = 0.04). The per patient target lesion revascularization rate at 1 year was 17.1%. One year survival free from major adverse cardiac events was 77.1%.</p><p><b>CONCLUSIONS</b>Treatment of LM bifurcation lesions using DES is a safe and feasible way with a low one-year mortality. The need for revascularization in 17% of patients demands for improvement.</p>
Biblioteca responsable: WPRO